| abstract |
Provided herein are small molecule inhibitors against targets or IRE1 protein family members. The binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Further, the IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is solid or hematological cancer. [Selection diagram] Figure 1 |